In a letter to the company, the FDA cited safety and dosage concerns as major factors in their decision.
Thomas Castles
Advertisement
Articles by Thomas Castles
The drug helped patients achieve clinical remission, low disease activity.
Advertisement
Latest Updated Articles
Upadacitinib Meets Primary, Secondary Endpoints for RA TreatmentPublished: June 8th 2017 | Updated:
FDA Rejects Lilly's BaricitinibPublished: July 25th 2017 | Updated:
Advertisement
Advertisement